Javier Méndez

Médico oncólogo oaxaqueño, amante del béisbol, las Chivas y el mezcal 🦗🩺🦀 ⚾️ 🏟️ 🪓 🧢. ⚽️ 🔴⚪️🍿⚡️📚 🎶 🪲

[Oscar Arrieta @ogarrieta]

Diagnóstico y respuesta a tratamiento en cáncer de mama

Destaco la reciente revisión sobre la utilidad de la mamografía por emisión de positrones (PEM) en las distintas etapas abordadas del cáncer de mama, publicada por el Dr. Osvaldo García Pérez, la Dra. Irma Soldevilla Gallardo y la Dra. Quetzali Pitalua Cortés del @INCanMX.

#INCanInvestiga #PublicacionesINCan

[Dr Sarah Sammons @drsarahsam]

ELECTRA (Phase 1b/2, interim Phase 2 data): elacestrant + abemaciclib in ER+/HER2- metastatic breast cancer with active brain mets, presented at the 2026 SNO/ASCO CNS Metastases Conference.

Both agents cross the BBB, reaching clinically meaningful plasma and CSF concentrations.

Efficacy in the interim analysis (patients with active brain mets, per BICR):

Overall RECIST v1.1 (n=21): ORR 14.3%, CBR-24wk 23.8%
Intracranial RECIST v1.1 (n=16): ORR 12.5%, CBR-24wk 25.0%
RANO-BM (n=16): ORR 18.8%, CBR-24wk 31.3%

That's a 2-3x jump in ORR vs historical endocrine therapy regimens, in a population that often has limited options.

One fatal carotid thrombosis (abemaciclib-related) led to revised eligibility criteria to reduce VTE risk.

Lin N, et al. 2026 SNO/ASCO CNS Metastases Conference, Abstract CLTR-07. NCT05386108 @nlinmd

[Yakup Ergün @dr_yakupergun]

OlympiA update: One year of adj olaparib in pts with high-risk, gBRCA1/2-mutated, HER2- eBC maintains an approximately 9% iDFS benefit and 4% OS benefit at 6 years. The benefit remains consistent across the key subgroups, with no late MDS/AML safety signal to date.

Questions regarding pembro and CDK4/6is still remain!

https://t.co/RSkEgdBTLK

[Yakup Ergün @dr_yakupergun]

In the phase Ib/ II ELEVATE trial, elacestrant plus everolimus achieved a mPFS of 8.3 mo and an ORR of 19.5% in ER+/HER2− mBC after CDK4/6i

Taken together with evERA and VIKTORIA-1, these findings suggest that the main potential of oral SERDs may lie less in monotherapy and more in serving as an endocrine backbone for PI3K/AKT/mTOR pathway inhibitors.

https://t.co/rrL7T2eqGl

[Megan Rech, PharmD, MS @MeganARech]

Very excited to share our State of the Art review entitled Diagnosis and Management of Acute Hyperkalaemia published in @bmj_latest

✅Check it out for a nice overview of the epidemiology and pathophysiology of hyperkalaemia, key risk factors and diagnostic considerations, and evidence based approaches to acute management
https://t.co/UVuPa2fiFG
@LRayRx @DEZ_EM_Pharm @DharatiDesai @gavin_howington @MileHighEMCCM

[Signal Transduction and Targeted Therapy (STTT) @sigtrans_sttt]

First-in-class #Oncology drugs are reshaping #CancerTherapy via novel targets, precision strategies & emerging modalities.

This review maps global innovation and highlights challenges limiting their clinical translation. @PKU1898 @Tsinghua_Uni

#STTT #OpenAccess: https://t.co/hvDJSMTnkz

[Mirrors of Medicine @mirrorsmed]

🧴  Does topical diclofenac actually prevent capecitabine-induced hand-foot syndrome in everyday practice?

Article 📰
https://t.co/1AJr83XaT2

Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study

A prospective real-world study of 151 patients with colorectal or gastric cancer found that prophylactic 1% topical diclofenac💊 🧴 did not 🚫 prevent clinically significant capecitabine-induced hand-foot syndrome. Grade ≥2 HFS occurred in 16.9% with diclofenac versus 13.8% with active monitoring, with no difference in time to onset or HFS-related dose reductions. Female sex and capecitabine monotherapy were independently associated with grade ≥2 HFS. ➡️ Routine diclofenac prophylaxis is therefore 🙅 not supported.

@DrOzanYazc1
@FatihGurlerMD
@uyargalip
@Xesiloglu
@ugur_coskun_
@kbaskurtt
@OzetAhmet
@nuriyeozdemir71
@osutcuoglu

[Yakup Ergün @dr_yakupergun]

NeoZanHER explored whether chemotherapy could be omitted in small, node-negative HER2+ breast cancer using neoadjuvant zanidatamab ± endocrine therapy.

Among 20 patients with 1–3 cm, N0 tumors:

• pCR: 30% overall; 40% in IHC 3+
• pCR/RCB-1: 50%
• No grade ≥3 TRAEs
• No pCR in IHC 2+/ISH+ disease‼️

The treatment was active and well tolerated, but its relevance should be considered alongside PHERGain and PHERGain-2.

PHERGain already showed that a PET- and pCR-adapted HP strategy could spare chemotherapy in approximately one-third of a broader stage I–IIIA population, with 3-year iDFS of 94.8%. In the latest analysis, 5-year iDFS was 92.4% in the PET-responder/pCR subgroup that never received chemotherapy.

PHERGain-2 then selected 396 patients with 5–30 mm, N0, centrally confirmed IHC 3+ tumors. Eight cycles of HP ± endocrine therapy produced a 59.6% pCR rate, with residual disease escalated to T-DM1.

Cross-trial comparisons are imperfect, but zanidatamab has not yet shown a stronger efficacy signal than HP. Its potential value lies in replacing two antibodies with a single bispecific agent and in refining biological selection.

The next trial must show what zanidatamab adds beyond PHERGain-2: better selection, shorter treatment, lower toxicity, or durable outcomes.

https://t.co/70DXJwHBej

[Olympiacos FC @olympiacosfc]

¡Bienvenido al Olympiacos, Armando! 🔴⚪️

#OlympiacosFC #Greece #Mexico

[Hussein Tawbi, MD, PhD @HTawbi_MDPhD]

This is a landmark moment in melanoma, cancer immunology, & IO drug development at large. Checkpoint inhibitors have allowed us to uncover & amplify the immune impact of cancer therapies we used for decades (e.g.,chemo, RT). Now, coupled with the powerful mRNA vaccine technology, finally unlocked the potential for personalized immunotherapy. Congrats to @Merck & @moderna_tx Grateful for our patients & research teams that allowed to participate in such a monumental accomplishment!

[Dr Rupam Manna MD @DrRupamOncology]

📊 Evolution of Adjuvant Therapy in Breast Cancer
My latest high-yield practical guide on landmark trials that transformed post-surgical treatment — from uniform chemotherapy to precision, subtype-driven care (2026 update).
✅ HR+/HER2–: Genomic de-escalation (TAILORx, RxPONDER) + CDK4/6i escalation (monarchE, NATALEE)
✅ HER2+: Trastuzumab era → dual blockade (APHINITY) + T-DXd for residual disease (KATHERINE/DESTINY-Breast05)
✅ TNBC: Perioperative pembrolizumab (KEYNOTE-522) + olaparib for BRCA+ (OlympiA)
✅ Biomarker-driven de-escalation & escalation based on risk & genomics
Essential for breast oncology, precision medicine & exam prep.
Save it 📌 Share it with your team & trainees 👇
Which landmark trial changed your practice the most in early breast cancer? Feedback & discussions welcome!
#BreastCancer #AdjuvantTherapy #Oncology #PrecisionMedicine #MedEd #OncoTwitter #BCSM
— Dr Rupam Manna
Medical Oncologist

[Yakup Ergün @dr_yakupergun]

CDK4/6 inhibitors may do more than just stop the cell cycle.

Senescent cells no longer divide, but they continue to produce an inflammatory secretome (SASP), which may contribute to aging, post-treatment functional decline, and tumor progression.

Two studies in Nature Aging show that CDK4/6 inhibition can suppress this secretome through the cGAS–STING and RARα/NF-κB pathways.

Abemaciclib reduced the pro-tumorigenic effects of chemotherapy-induced senescent cells, while palbociclib reduced inflammation and improved physical performance in aged mice.

An interesting potential role for CDK4/6 inhibitors beyond oncology.

https://t.co/fc5mflQOwb

[Enrique Grande @drenriquegrande]

SITC clinical practice guideline (v3.0) on immunotherapy in RCC: updated recommendations across adjuvant and metastatic settings, special populations, response monitoring, and QoL.

PD-L1/TMB/MSI do not guide selection. Sarcomatoid features favor IO — nivo/ipi remains a preferred option.

https://t.co/oDPnQzWxK8

#KidneyCancer

[Javier Méndez @DrPatronus]

@GunnerPuls Easy. James Rodríguez.

[Javier Méndez @DrPatronus]

@raffcolo Thank you for sharing this often-underestimated aspect of ADCs; we frequently overlook the importance of the linker. I am a fan of your work, and it is exciting to see the update to your excellent 2024 paper. https://t.co/3wDAnuEm25

[Raffaele Colombo @raffcolo]

https://t.co/bwKasq4NhT

Narrative review on PK modeling for ADCs

One major oversight is that only a few linkers generate free payload via linker instability. For majority of ADCs, instability releases the intact drug-linker, which reconjugates to plasma thiols (e.g. albumin)!

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New study in @ESMO_Open 👉 Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study.
🔓https://t.co/pDJEZzFdgs
@hoperugo @jhaveri_komal @SoniaPernas @BarbaraPistill2 @MicheleDelauren @ErikaHamilton9 @KalinskyKevin @stolaney1 @dradityabardia #MBC
#BreastCancer #MetastaticBreastCancer #DatoDXd

[Yakup Ergün @dr_yakupergun]

DCIS Management in 2026: A Practical NCCN-Based Algorithm for Clinicians

(AI-assisted infographic. Content reviewed)

[Javier Méndez @DrPatronus]

@Camberismo_12 No sé cuál salida me dolió más, pero en mi top están:

- Bofo Bautista a Jaguares.

- Rodolfo Pizarro a Monterrey.

- Oswaldo a Santos Laguna.

[Oscar Arrieta @ogarrieta]

Subtipos moleculares y linfocitos infiltrantes en el cáncer de mama triple negativo.

Una revisión que analiza su relevancia en pacientes con tratamiento de quimioterapia, con la participación del Dr. Alejandro Mohar, Dra. Paula Cabrera @anelcabrera, Dra. Fany Porras, Dr. Víctor Pérez, Dr. César Lara, Dra. Areli Velázquez, Dr. Alejandro Aranda del @incanMX, y cols.